Stay updated on Tislelizumab vs Chemotherapy in Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Tislelizumab vs Chemotherapy in Esophageal Cancer Clinical Trial page.

Latest updates to the Tislelizumab vs Chemotherapy in Esophageal Cancer Clinical Trial page
- ChecktodayChange DetectedThe study record no longer lists the “2017 (U.S. NIH Grant/Contract)” identifier, and the site revision advances from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoChange DetectedThe study record describes a completed Phase 3 comparison of tislelizumab with chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma. It also provides trial eligibility, participating locations, study outcomes, publications, and protocol documents.SummaryDifference100%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA sitewide NIH banner announces updates and FAQs about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check35 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2, while the study page remains an access-denied error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

Stay in the know with updates to Tislelizumab vs Chemotherapy in Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Chemotherapy in Esophageal Cancer Clinical Trial page.